Kim M S, Lee S I, Sim J H
Department of Neurological Surgery, Inje University Pusan Paik Hospital, Pusan, Korea.
Stereotact Funct Neurosurg. 1999;72 Suppl 1:119-24. doi: 10.1159/000056447.
Transsphenoidal microsurgery remains the treatment of choice for pituitary microadenomas One hundred and six patients were treated with Gamma Knife radiosurgery (GKRS) for pituitary adenomas, and of these, 23 patients (1 male, 22 female) had microadenomas. Twenty-two of these patients were followed up and endocrinological tests were available for 15 of these 22. Thirteen of these 15 had prolactinomas, while the remaining 2 had acromegaly. The follow-up period was from 3 to 26 months (median 12 months). The mean age was 33.6 years (range 21 to 60 years). The mean maximum tumor dose was 35.7 Gy and the mean margin dose was 22 Gy. Serum prolactin (PRL) was normalized in three patients, decreased in eight and unchanged in two. The growth hormone (GH) secretion in the acromegalic patients has remained unchanged through the follow-up period. Thus, GKRS is a valuable adjuvant to transsphenoidal microsurgery for patients with pituitary microadenomas.
经蝶窦显微手术仍是垂体微腺瘤的首选治疗方法。106例垂体腺瘤患者接受了伽玛刀放射外科治疗(GKRS),其中23例(1例男性,22例女性)为微腺瘤。这23例患者中有22例进行了随访,22例中的15例可进行内分泌检查。这15例中有13例为催乳素瘤,其余2例为肢端肥大症。随访时间为3至26个月(中位时间12个月)。平均年龄为33.6岁(范围21至60岁)。平均最大肿瘤剂量为35.7 Gy,平均边缘剂量为22 Gy。3例患者血清催乳素(PRL)恢复正常,8例下降,2例无变化。肢端肥大症患者的生长激素(GH)分泌在随访期间保持不变。因此,对于垂体微腺瘤患者,GKRS是经蝶窦显微手术的一种有价值的辅助治疗方法。